Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #4209 on Antares Pharma, Inc. (ATRS)
H2R
05/18/17 3:28 PM
#4210 RE: H2R #4209
Antares Pharma ( ATRS ) said a phase 3 study of its QuickShot testosterone auto injector met its primary endpoint, increasing testosterone levels in men with hypogonadism. The company will present phase 3 data on the pharmacokinetics and safety of QuickShot at the American Urological Association annual meeting in Boston, Massachusetts May 16.